Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prospective Study of FTD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma.

NCT05274139 is registered in ClinicalTrials.gov with Mingzhi Zhang as lead sponsor.

NCT NCT05274139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05274139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prospective Study of FTD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma.
Lead sponsor
Mingzhi Zhang
Phase
Phase 2
Overall status
Completed
Start date
March 2, 2017
Completion date
March 2, 2019
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary cns lymphoma (pcnsl)